Alliance Pharma PLC Director Shareholding (8873N)
January 23 2019 - 4:06AM
UK Regulatory
TIDMAPH
RNS Number : 8873N
Alliance Pharma PLC
23 January 2019
23 January 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, was notified on 22 January 2019 that on 22 January 2019
Richard Jones, a Non-Executive Director of the Company, purchased
15,000 ordinary shares of 1.0p each in the Company ("Ordinary
Shares") at a price of 65.28 pence per share.
Following this transaction, Mr Jones' total beneficial interest
in the Company is 15,000 Ordinary Shares, representing less than
0.01% of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Richard Jones
-------------------------------------- ----------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------------------- ----------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Alliance Pharma Plc
-------------------------------------- ----------------------------------
b) Legal Entity 213800RYIWZA4Q5WPZ13
Identifier
-------------------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument, GB0031030819
type of instrument
Identification
code
-------------------------------------- ----------------------------------
b) Nature of Purchase of shares
the transaction
-------------------------------------- ----------------------------------
c) Currency GBP
-------------------------------------- ----------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
-------------------------------------- --------------- -----------------
65.28p 15,000
------------------------------------------- --------------- -----------------
e) Aggregated
information n/a
- Aggregated
volume
- Price
- Aggregated
total
-------------------------------------- ----------------------------------
f) Date of the 22 January 2019
transaction
-------------------------------------- ----------------------------------
g) Place of London Stock Exchange, AIM
the transaction
-------------------------------------- ----------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade /
Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
David Herring
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with affiliate offices in Europe,
the Far East and the US and wide international reach through an
extensive network of distributors, generating sales in more than
100 countries.
We currently own or license the rights to more than 90
pharmaceutical and consumer healthcare products, which are managed
on a portfolio basis according to their growth potential.
Promotional investment is focussed on a small number of brands with
significant international or multi-territory reach. The remainder
of the portfolio comprises products which are sold in a limited
number of local markets and require little or no promotional
investment.
Our tried and tested 'Buy and Build' strategy, allows us to
benefit both from organic growth opportunities and from enhancing
our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUORRRKOAAUAR
(END) Dow Jones Newswires
January 23, 2019 05:06 ET (10:06 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024
